Index Entries - Covid Index

1774 Results

Title	IS Publication Date
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia	November 21, 2023
Risk of severe COVID-19 infection among adults with prior exposure to children	July 27, 2022
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study	August 26, 2021
Risk stratification for future cardiac arrest after COVID-19 vaccination	February 26, 2025
Risks of Covid-19 face masks to wildlife: Present and future research needs	October 20, 2021
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	December 14, 2021
Roadmap for the Implementation of Actions by the European Commission based on the Commission Communication and the Council Recommendation on Strengthening Cooperation against Vaccine Preventable Diseases	Last update Q3 2019
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months	December 4, 2020
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection	March 5, 2021
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19	August 14, 2020
Rochelle Walensky on the risk of COVID-19 vaccines for 12-17 year olds	June 24, 2021
Role of hydroxychloroquine in multidrug treatment of COVID-19	September 24, 2021
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study	February 16, 2021
Rush to Use Ventilators Killed Thousands of COVID Patients	September 18, 2024
S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study	June 30, 2020
Sacrifice: How the Deadliest Vaccine in History Targeted the Most Vulnerable	February 18, 2025
Safe and Effective: A Second Opinion	September 28, 2022
Safe Nanoparticles: Are We There Yet?	December 31, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	November 4, 2021
Safety and Health Guidance: COVID-19 Infection Prevention for Logistics Employers and Employees	October 27, 2020
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data	February 26, 2024
Safety of COVID-19 Vaccines: Spotlight on Neurological Complications	August 29, 2022
Safety of mRNA Vaccines Administered During the First Twenty-Four Months of the International COVID-19 Vaccination Program	April 10, 2023
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	September 16, 2021
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry	December 31, 2021
Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis	December 15, 2022
Safety Signals for COVID Vaccines Are Loud and Clear. Why Is Nobody Listening?	September 29, 2021
SARS-CoV-2 and the Vaccination Hype	January 17, 2022
SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions	November 24, 2022
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy	April 27, 2021
SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021	December 17, 2021
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	September 8, 2020
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity	June 4, 2021
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans	May 24, 2021
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19	March 22, 2021
SARS-CoV-2 Is an Unrestricted Bioweapon: A Truth Revealed through Uncovering a Large-Scale, Organized Scientific Fraud	October 8, 2020
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers	May 20, 2021
SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis	August 30, 2021
SARS-COV-2 mRNA Vaccine (BNT162, PF-07302048) — 2.6.4 Summary statement of the pharmacokinetic study
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels	September 17, 2020
SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro	March 21, 2022
SARS-CoV-2 re-infection risk in Austria	February 13, 2021
SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome	December 13, 2020
SARS-CoV-2 S1 Protein Persistence in SARS-CoV-2 Negative Post-Vaccination Individuals with Long COVID/ PASC-Like Symptoms	July 12, 2022
SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia	October 28, 2021
SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination	January 17, 2023
SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19	April 5, 2023
SARS-CoV-2 spike protein alone may cause lung damage	April 27, 2021
SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells	November 23, 2021

Page 27 of 36